Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616071 | 1.00 | ERN1 (0.44) | ERN1CISD1TRIM24TRIM33ESR1 | |
| SCHEMBL3562577 | 0.92 | ERN1 (0.44) | ERN1TRIM24TRIM33ESR1ESR2 | |
| SCHEMBL874654 | 0.83 | ERN1 (0.48) | ERN1TRIM24TRIM33 | |
| SCHEMBL415162 | 0.82 | ERN1 (0.50) | ERN1TRIM24TRIM33ESR1ESR2 | |
| SCHEMBL1464801 | 0.82 | ERN1 (0.50) | ERN1TRIM24TRIM33 | |
| SCHEMBL29655114 | 0.80 | ERN1 (0.43) | ERN1TRIM24TRIM33 | |
| SCHEMBL933374 | 0.80 | ERN1 (0.43) | ERN1TRIM24TRIM33 | |
| SCHEMBL6782431 | 0.80 | ERN1 (0.48) | ERN1CISD1TRIM24TRIM33 | |
| SCHEMBL1860423 | 0.80 | ERN1 (0.54) | ERN1CISD1TRIM24TRIM33 | |
| SCHEMBL30064066 | 0.80 | ERN1 (0.54) | ERN1CISD1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2025051216-A1 | CYP11A1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳众格生物科技有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-114585609-B | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240116909-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| WO-2024032782-A1 | VACCINE ADJUVANTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO.LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313962-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101616913-A | Fused ring compound | TAKEDA PHARMACEUTICAL | 2009-12-30 | — | — | CN | disclosed |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1878727-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116909-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, CGAS, IRF3 | ERN1 507/4885CISD1 1516/4885TRIM24 730/4885 |
| US-20090137583-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | SLC7A1, SLC38A7, PRMT7 | ERN1 2633/4885CISD1 2073/4885TRIM24 3439/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ERN1 2727/4885CISD1 2906/4885TRIM24 3254/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ERN1 1311/4885CISD1 2367/4885TRIM24 3745/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | ERN1 256/4885CISD1 1991/4885TRIM24 3302/4885 |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | ERN1 2228/4885CISD1 2190/4885TRIM24 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.